Opposing effects of apolipoprotein m on catabolism of apolipoprotein b-containing lipoproteins and atherosclerosis

Circulation Research

Volumn 106, Issue 10, 2010, Pages 1624-1634

  Christoffersen, Christina ^a   Pedersen, Tanja Xenia ^b   Gordts, Philip L S M ^c   Roebroek, Anton J M ^c   Dahlbäck, Björn ^d   Nielsen, Lars Bo ^a,b  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Department of Laboratory Medicine   (Sweden)

Author keywords

Apolipoprotein M; Atherosclerosis; Lipid metabolism

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN M; CHOLESTEROL; CHOLIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL INTAKE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CROSSES, GENETIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS, VLDL; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 77953029027     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.211086     Document Type: Article

References (40)

1. Kane J, Havel R. Disorders of the biogenesis and secretion of lipoproteins containing the apoB apolipoproteins. In: Scriver C, Beaudet AL, Sly WS, Valle P, eds. The Metabolic and Molecular Bases for Inherited Diseases. 8th ed. New York: McGraw-Hill; 2001:2717-2752.
2. Goldstein J, Hobbs H, Brown M. Familial hypercholesterolemia. In: Scriver C, Beaudet AL, Sly WS, Valle P, eds. The Metabolic and Molecular Bases for Inherited Diseases. 8th ed. New York: McGraw-Hill; 2001:2863-2913.
3. Tall AR, Breslow JL, Rubin EM. Genetic disorders affecting plasma high-density lipoproteins. In: Scriver C, Beaudet AL, Sly WS, Valle P, eds. The Metabolic and Molecular Bases for Inherited Diseases. 8th ed. New York: McGraw-Hill; 2001:2915-2936.
4. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-756.
5. Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem. 2003;105:67-72.
6. Faber K, Axler O, Dahlback B, Nielsen LB. Characterization of apoM in normal and genetically modified mice. J Lipid Res. 2004;45:1272-1278.
7. Faber K, Hvidberg V, Moestrup SK, Dahlback B, Nielsen LB. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol. 2006;20: 212-218.
8. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res. 2007;48:1772-1780.
9. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem. 1999;274:31286-31290.
10. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 2006;47:1833-1843.
11. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apoli-poprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett. 2001;499:127-132.
12. Christoffersen C, Ahnstrom J, Axler O, Christensen EI, Dahlback B, Nielsen LB. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem. 2008;283:18765-18772.
13. Axler O, Ahnstrom J, Dahlback B. Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett. 2008;582: 826-828.
14. Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlback B, Nielsen LB. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem. 2008;283:1839-1847.
15. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11:418-422.
16. Plomgaard P, Dullaart RP, de VR, Groen AK, Dahlback B, Nielsen LB. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med. 2009;266:258-267.
17. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24: 421-428.
18. Ahnstrom J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, Frikke-Schmidt R, Tybjaerg-Hansen A, Dahlback B. Levels of apoli-poprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res. 2008;49:1912-1917.
19. Brunzell J, Deeb S. Familial lipoprotein lipase deficiency, apoCII deficiency and hepatic lipase deficiency. In: Scriver C, Beaudet AL, Sly WS, Valle P, eds. The Metabolic and Molecular Bases for Inherited Diseases. 8th ed. New York: McGraw-Hill; 2001:2789-2816.
20. Fisher WR, Zech LA, Kilgore LL, Stacpoole PW. Metabolic pathways of apolipoprotein B in heterozygous familial hypercholesterolemia: studies with a [3H]leucine tracer. J Lipid Res. 1991;32:1823-1836.
21. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985;1:1-39.
22. Brown MS, Goldstein JL. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest. 1983;72:743-747.
23. Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC, Boston RC, Tada N, Mochizuki S, Defesche JC, Wilson JM, Rader DJ. Complete deficiency of the low-density lipoprotein receptor is asso-ciated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol. 2005;25:560-565.
24. Langer T, Strober W, Levy RI. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest. 1972;51:1528-1536.
25. Pittman RC, Carew TE, Attie AD, Witztum JL, Watanabe Y, Steinberg D. Receptor-dependent and receptor-independent degradation of low density lipoprotein in normal rabbits and in receptor-deficient mutant rabbits. J Biol Chem. 1982;257:7994-8000.
26. Mortimer BC, Beveridge DJ, Martins IJ, Redgrave TG. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. J Biol Chem. 1995;270:28767-28776.
27. Fuki IV, Iozzo RV, Williams KJ. Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem. 2000;275:25742-25750.
28. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
29. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101:689-695.
30. Magoori K, Kang MJ, Ito MR, Kakuuchi H, Ioka RX, Kamataki A, Kim DH, Asaba H, Iwasaki S, Takei YA, Sasaki M, Usui S, Okazaki M, Takahashi S, Ono M, Nose M, Sakai J, Fujino T, Yamamoto TT. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem. 2003;278:11331-11336.
31. Hu L, van der Hoogt CC, Espirito Santo SM, Out R, Kypreos KE, van Vlijmen BJ, Van Berkel TJ, Romijn JA, Havekes LM, van Dijk KW, Rensen PC. The hepatic uptake of VLDL in lrp-ldlr\/\vldlr\/\mice is regulated by LPL activity and involves proteoglycans and SR-BI. J Lipid Res. 2008;49:1553-1561.
32. Gordts PL, Reekmans S, Lauwers A, Van DA, Verbeek L, Roebroek AJ. Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1258-1264.
33. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883-893. (Pubitemid 23262411)
34. Marcel YL, Innerarity TL, Spilman C, Mahley RW, Protter AA, Milne RW. Mapping of human apolipoprotein B antigenic determinants. Arteriosclerosis. 1987;7:166-175.
35. Veniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest. 1998;102:1559-1568.
36. Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest. 1998;101:1726-1736.
37. Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE, Brewer HB Jr. In vivo metabolism of apoli-poprotein A-I in a patient with homozygous familial hypercholesterol-emia. Arterioscler Thromb. 1992;12:843-848.
38. Grundy SM, Vega GL, Bilheimer DW. Kinetic mechanisms determining variability in low density lipoprotein levels and rise with age. Arteriosclerosis. 1985;5:623-630.
39. Ahnstrom J, Faber K, Axler O, Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res. 2007; 48:1754-1762.
40. Wu X, Niu N, Brismar K, Zhu X, Wang X, Efendic S, Du T, Liu Y, Gu HF, Liu Y. Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. Clin Biochem. 2009;42:17-21.